MedPath
HSA Approval

SPIRIVA® RESPIMAT® RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM

SIN15885P

SPIRIVA® RESPIMAT® RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM

SPIRIVA® RESPIMAT® RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM

February 18, 2020

BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.

BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Licence HolderBOEHRINGER INGELHEIM SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION

**4.2 Posology and method of administration** Posology The medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat inhaler (see 4.2). Two puffs from the Respimat inhaler comprise one medicinal dose. The recommended dose for adults is 5 microgram tiotropium given as two puffs from the Respimat inhaler once daily, at the same time of the day. The recommended dose should not be exceeded. In the treatment of asthma, the full benefit will be apparent after several doses of the medicinal product. Special populations Geriatric patients can use tiotropium bromide at the recommended dose. Renally impaired patients can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance ≤ 50 ml/min, see 4.4 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hepatically impaired patients can use tiotropium bromide at the recommended dose (see 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Paediatric population COPD SPIRIVA RESPIMAT re-usable is not recommended for use in children and adolescents below 18 years due to lack of data on safety and efficacy (see 5.1 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Asthma In asthma, the recommended dosage of tiotropium using the SPIRIVA RESPIMAT re-usable in patients 6 to 17 years of age is 5 micrograms. This is administered as two puffs once daily from the RESPIMAT inhaler, at the same time each day (see RESPIMAT inhaler Instructions for Use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). SPIRIVA RESPIMAT re-usable has not been studied in children less than 1 year old. Method of administration To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler by a physician or other health professionals.

RESPIRATORY (INHALATION)

Medical Information

**4.1 Therapeutic indications** COPD SPIRIVA RESPIMAT re-usable is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). Asthma SPIRIVA RESPIMAT re-usable is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.

**4.3 Contraindications** SPIRIVA RESPIMAT re-usable is contraindicated in patients with hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to any of the excipients (see 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

R03BB04

tiotropium bromide

Manufacturer Information

BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim España, S.A.

Active Ingredients

Tiotropium bromide monohydrate eqv tiotropium

0.0025 mg/actuation

Tiotropium

Documents

Package Inserts

Spiriva SG_Proposed PI (clean) rev 21Feb2022.pdf

Approved: August 31, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SPIRIVA® RESPIMAT® RE-USABLE SOLUTION FOR INHALATION 2.5 MICROGRAM - HSA Approval | MedPath